Heat Biologics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HTBX research report →
Price Chart
About the company
Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases.
- CEO
- Jeffrey Wolf
- IPO
- 2013
- Employees
- 49
- HQ
- Morrisville, NC, US
Get TickerSpark's AI analysis on HTBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $61.07M
- P/E
- -21.64
- PEG
- 2.06
- P/S
- 133.53
- P/B
- -1.09
- EV/EBITDA
- 4.00
- Div Yield
- 0.00%
- Gross Margin
- 488.07%
- Op Margin
- -11598.69%
- Net Margin
- -11073.41%
- ROE
- 26.55%
- ROIC
- 0.00%
Latest fiscal year · YoY change
- Revenue
- $2.11M-28.3%
- Gross Profit
- $2.11M-28.3%
- Op Income
- $-35,419,039
- Net Income
- $-35,400,807-35.9%
- EPS
- $-1.41+13.5%
- OCF Growth
- +100.0%
- FCF Growth
- +100.0%
- 52W High
- $10.85
- 52W Low
- $1.60
- 50D MA
- $2.57
- 200D MA
- $4.11
- Beta
- 0.30
- RSI (14)
- 40
- Avg Volume
- 155.10K
No earnings-call transcripts are available for HTBX yet.
- Free Float
- 94.5%
- Shares Outstanding
- 25.66M
- Float Shares
- 24.26M
of shares held by institutions
1 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Etrade Capital Management LLC | 25.63K | ▲ 25.63K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 30, 21 | Smith Edward B III | other | 32,467 |
| Dec 30, 21 | Smith Edward B III | other | 32,467 |
| Dec 13, 21 | Smith Edward B III | other | 32,467 |
| Dec 13, 21 | Ostrander William L. | other | 68,807 |
| Jan 4, 21 | Smith Edward B III | other | 65,217 |
| Jan 4, 21 | Ostrander William L. | other | 51,487 |
| Nov 12, 20 | Smith Edward B III | sell | 103,304 |
| Aug 13, 20 | Ostrander William L. | other | 15,625 |
| Aug 13, 20 | Ostrander William L. | other | 15,625 |
| Aug 13, 20 | Ostrander William L. | other | 4,440 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HTBX coverage
Recent articles, reports, and earnings notes.
No research on HTBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HTBX report →Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today
globenewswire.com · May 3
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics
globenewswire.com · Apr 20
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
globenewswire.com · Apr 19
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments
globenewswire.com · Apr 18
Heat Biologics' Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility
globenewswire.com · Apr 18
Heat Biologics' Announces Planned Investor and Media Livestream Event to Discuss Latest Developments
globenewswire.com · Apr 14
Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process
globenewswire.com · Mar 25
Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
globenewswire.com · Mar 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.